Madam Chair, as Minister Hajdu noted, we do work on a rolling submission basis through data from preclinical to clinical to quality data or data pertaining to manufacturing. We issue drug establishment licences for those establishments that would be producing the actual vaccines that Canada would access. That process is happening on an extraordinarily expedited basis.
As noted previously, we do work in collaboration with international regulators, but in the end, we need to review the final data that is pertinent to the authorization in Canada and make that assessment based on our independent scientific review. We're doing that by literally working around the clock with independent teams dedicated to each vaccine. We'll work to conclude that review, in particular, AstraZeneca, as quickly as possible, with the final information provided by the manufacturer when it comes.